juglone and tretinoin
juglone has been researched along with tretinoin in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cao, R; Chen, H; Chen, X; Cui, G; Jin, J; Xu, B | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Buscarlet, M; Ciarapica, R; Dali, R; del Sal, G; Lo, R; Locatelli, F; Methot, L; Rota, R; Stifani, S; Tang, Y | 1 |
| Imamura, Y; Kato, M; Leung, JK; Mawji, NR; Sadar, MD; Wang, J | 1 |
Other Studies
4 other study(ies) available for juglone and tretinoin
| Article | Year |
|---|---|
Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Humans; NIMA-Interacting Peptidylprolyl Isomerase; Protein Binding; Pyrimidines; Recombinant Proteins; Structure-Activity Relationship | 2018 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Prolyl isomerase Pin1 and protein kinase HIPK2 cooperate to promote cortical neurogenesis by suppressing Groucho/TLE:Hes1-mediated inhibition of neuronal differentiation.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Carrier Proteins; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; HEK293 Cells; Homeodomain Proteins; Humans; Mice; Naphthoquinones; Neural Stem Cells; Neurogenesis; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Protein Serine-Threonine Kinases; Repressor Proteins; Transcription Factor HES-1; Tretinoin | 2014 |
Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Male; Mice, Inbred NOD; Mice, SCID; Naphthoquinones; NIMA-Interacting Peptidylprolyl Isomerase; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Receptors, Androgen; Signal Transduction; Tretinoin; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |